Compare Amazon.com Inc (AMZN) vs Summit Therapeutics Inc (SMMT) Price & Performance

Amazon (AMZN) trades at $272.27, down 2.09% today but maintains strong fundamentals with robust revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Technical indicators show a bullish trend with support at $271 and resistance at $275, while analyst consensus remains overwhelmingly positive with 89% buy ratings and a $333.86 price target. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS growth and AI chip business expansion.

Amazon presents a compelling investment case with accelerating profitability and dominant market positioning, though investors face risks from intense competition and significant capital expenditures. The stock's current valuation at 21.9x P/E appears reasonable given projected 2026 net income growth to $135.3B, supporting potential upside to analyst targets despite near-term market volatility.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.